Treatment of non-Hodgkin lymphoma and mature В-cell acute leukemia in children and adolescents: data of Russian regional hospitals
https://doi.org/10.17650/1818-8346-2011-6-1-30-34
Abstract
The article presents treatment results of 233 patients (children and adolescents under 19 years old; median — 8.76 years) with CD20-
positive non-Hodgkin lymphomas and B-cell acute leukemia (B-NHL/B-AL) received chemotherapy (BFM B-NHL 90–95 protocols) or combined chemo-immunotherapy with rituximab (B-NHL-2004mab protocol). Combined chemo-immunotherapy was used for patients with Burkitt lymphoma, diffuse large cells lymphomas stage III–IV and B-AL, and included cytoreductive phase, 6 polychemotherapy (PCT) courses and rituximab. PCT courses are similar to those of original BFM B-NHL90 protocol, except for the first 2 courses, where daily methotrexate dose was reduced from 5 to 1 g/m2/24 h. Rituximab infused IV 12 hours before the start of first 4 chemotherapy courses at a dose of 375 mg/m2. The data in the questionnaires form have been submitted from 28 pediatric specialized hospitals from 27 Russia regions over the past 5 years (2005–2009). Protocol with rituximab has proved to be more effective than chemotherapy alone. The authors discuss the possibility of using combined chemo-immunotherapy for the treatment of B-NHL/B-AL at regional hospitals and the prospects for further treatment results improvement in this group of tumors.
About the Authors
Ye. V. Samochatova
Federal Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation
Russian Federation
L. N. Shelikhova
Russian Children Clinical Hospital
Russian Federation
Russian Federation
References
1. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Jaffe E.S., Harris N.L., Stein H., Vardiman J.W. Lyon, 2001; p.181
2. Magrath I. The non-Hodgkin’s lymphomas in children. In Oxford Textbook of Oncology. Oxford Medical Publications, Oxford, 1995; p. 1809–51.
3. Patte C., Philip T., Rodary C. et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 1991;9:123–32.
4. Goldman S., Gerard M., Sposto R. et al. Exellent results in children and adolescents with isolated mature B-cell acute lymphoblastic leukemia (B-ALL) (Burkitt): Report from the FAB International LMB study FAB/LMB 96. Proc Am Hem 2005;106;Abstract 234:72a.
5. Reiter A., Schrappe M., Tiemann M. et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt- Munster Group Trial NHL-BFM-90. Blood 1999;94(10):3294–306.
6. Самочатова Е.В., Островская А.В., Карачунский А.И. и соавт. Значение верификации варианта неходжкинской лимфомы у детей для эффективности лечения по современным протоколам. Гематол и трансфузиол 2000;6:9–14.
7. Самочатова Е.В., Алейникова О.В., Беликова Л.Ю., Боридко А.Н. и соавт. Неходжкинские лимфомы у детей: клиническая характеристика, возможности диагностики и терапии (по данным клиник России и Беларуси). Гематол и трансфузиол 2001;1:1–10.
8. Островская А.В. Неходжкинские лимфомы у детей. Автореферат дис. … канд. мед. наук. М., 2004.
9. Minard-Colin V., Horikawa M., Xiu Y. Immune effector mechanisms of CD20 monoclonal antibodies. Hematology meeting reports 2009;3(5):19.
10. Pfreundshuh M.G.M. et al. Randomized intergroup trial of first-line treatment for patients < 60 years with diffuse large B-cell lymphoma (DLBCL) with a CHOP-like regimen with and without the anti-CD20 antibody rituximab — early stopping after first interim analysis. Blood 2002;11:A65.
11. Coiffer B., Lepage E., Brier J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235.
12. Samochatova E., Myakova N., Shelikhova L. et al. Preliminary results of treatment of pediatric advance-staged mature В-cell non-Hodgkin lymphomas/B-ALL with intensive chemotherapy + rituximab: effectiveness and toxicity. Pediatric Blood & Cancer 2006;46(issue7):854.
13. Самочатова Е.В., Шелихова Л.Н., Белогурова М.Б., Шамардина А.В. и соавт. Комбинированная химиоиммунотерапия больных неходжкинскими лимфомами из зрелых В-клеток возрастной группы до 18 лет: результаты многоцентрового исследования НХЛ 2004 М с применением ритуксимаба и модифицированного протокола В-НХЛ БФМ-90. Онкогематол 2009;3:4–14.
Review
For citations:
Samochatova Ye.V., Shelikhova L.N. Treatment of non-Hodgkin lymphoma and mature В-cell acute leukemia in children and adolescents: data of Russian regional hospitals. Oncohematology. 2011;6(1):30-34. (In Russ.) https://doi.org/10.17650/1818-8346-2011-6-1-30-34
Views:
10277
Email this article 